Wilson, JT. An update on the therapeutic orphan. Pediatrics
1999; 104 (3 Pt 2): 585–590.
Shah, SS, Hall, M, Goodman, DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med
2007; 161: 282–290.
Sutherell, JS, Hirsch, R, Beekman, RH 3rd. Pediatric interventional cardiology in the United States is dependent on the off-label use of medical devices. Congenit Heart Dis
2010; 5: 2–7.
Breslow, LH. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing. Harvard J Legis
2003; 40: 133–193.
Field, M, Boat, TF (eds). Safe and Effective Medicines for Children. Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act, 1st edn.
The National Academies Press, Washington, DC, 2012.
Ward, RM, Kauffman, R. Future of pediatric therapeutics: reauthorization of BPCA and PREA. Clin Pharmacol Ther
2007; 81: 477–479.
Berrington de Gonzalez, A, Mahesh, M, Kim, KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med
2009; 169: 2071–2077.
Hill, KD, Smith, PB, Cohen-Wolkowiez, M, Benjamin, DK, Li, JS. Pediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety. Clin Invest
2013; 3: 227–239.
Li, JS, Eisenstein, EL, Grabowski, HG, et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA
2007; 297 (5): 480–488.
Pasquali, SK, Lam, WK, Chiswell, K, Kemper, AR, Li, JS. Status of the pediatric clinical trials enterprise: an analysis of the US ClinicalTrials.gov registry. Pediatrics
2012; 130 (5): e1269–1277.
Hill, KD, Chiswell, K, Califf, RM, Pearson, G, Li, JS. Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov. American heart journal
2014; 167 (6): 921–929 e922.
Problems in Hodgkin’s disease management. Blood
1999; 93 (3): 761–779.
De Angelis, C, Drazen, JM, Frizelle, FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med.
2004; 351 (12): 1250–1251.
Califf, RM, Zarin, DA, Kramer, JM, Sherman, RE, Aberle, LH, Tasneem, A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010.
JAMA. 2012, 307 (17) 1838–1847.
Saul, JP, Ross, B, Schaffer, MS, et al. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. Clin Pharmacol Ther.
2001; 69 (3): 145–157.
Saul, JP, Schaffer, MS, Karpawich, PP, et al.
Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia. Journal of clinical pharmacology
2001; 41 (1): 35–43.
Benjamin, DK Jr., Smith, PB, Jadhav, P, et al.
Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension
2008; 51 (4): 834–840.
Shaddy, RE, Boucek, MM, Hsu, DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA
2007; 298 (10): 1171–1179.
Barst, RJ, Ivy, DD, Gaitan, G, et al.
A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation
2012; 125 (2): 324–334.
Barst, RJ, Beghetti, M, Pulido, T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation
2014; 129 (19): 1914–1923.
Wessel, DL, Berger, F, Li, JS, et al. Clopidogrel in infants with systemic-to-pulmonary-artery shunts. N Engl J Med.
2013; 368 (25): 2377–2384.
Felker, GM, Maisel, AS. A global rank end point for clinical trials in acute heart failure. Circulation. Heart failure
2010; 3 (5): 643–646.